Preclinical models of human peripheral arterial occlusive disease: Implications for investigation of therapeutic agents

Richard E. Waters, Ronald L. Terjung, Kevin G. Peters, Brian H. Annex

Research output: Contribution to journalArticle

Abstract

Peripheral arterial occlusive disease (PAOD) is now recognized as a combination of clinical syndromes that are associated with significant morbidity and mortality. The primary pathophysiology of PAOD is impaired perfusion to the lower extremity. Effective pharmacotherapy designed to increase perfusion in PAOD is lacking, and revascularization options are suboptimal. New and more efficacious therapies that improve blood flow are definitely needed, and thus designing, describing, and validating these new therapies in preclinical PAOD models will be essential. This study describes the various preclinical PAOD models presently in use, correlates the models to human PAOD, and reviews the available end points that can be used to detect a response to therapy.

Original languageEnglish (US)
Pages (from-to)773-780
Number of pages8
JournalJournal of Applied Physiology
Volume97
Issue number2
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Fingerprint

Arterial Occlusive Diseases
Peripheral Arterial Disease
Therapeutics
Perfusion
Lower Extremity
Morbidity
Drug Therapy
Mortality

Keywords

  • Angiogenesis
  • Endothelial cells
  • Growth factors
  • Perfusion
  • Vascular surgery

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Preclinical models of human peripheral arterial occlusive disease : Implications for investigation of therapeutic agents. / Waters, Richard E.; Terjung, Ronald L.; Peters, Kevin G.; Annex, Brian H.

In: Journal of Applied Physiology, Vol. 97, No. 2, 01.08.2004, p. 773-780.

Research output: Contribution to journalArticle

Waters, Richard E. ; Terjung, Ronald L. ; Peters, Kevin G. ; Annex, Brian H. / Preclinical models of human peripheral arterial occlusive disease : Implications for investigation of therapeutic agents. In: Journal of Applied Physiology. 2004 ; Vol. 97, No. 2. pp. 773-780.
@article{a0147eb0a12e41c596b2e0438248a3f8,
title = "Preclinical models of human peripheral arterial occlusive disease: Implications for investigation of therapeutic agents",
abstract = "Peripheral arterial occlusive disease (PAOD) is now recognized as a combination of clinical syndromes that are associated with significant morbidity and mortality. The primary pathophysiology of PAOD is impaired perfusion to the lower extremity. Effective pharmacotherapy designed to increase perfusion in PAOD is lacking, and revascularization options are suboptimal. New and more efficacious therapies that improve blood flow are definitely needed, and thus designing, describing, and validating these new therapies in preclinical PAOD models will be essential. This study describes the various preclinical PAOD models presently in use, correlates the models to human PAOD, and reviews the available end points that can be used to detect a response to therapy.",
keywords = "Angiogenesis, Endothelial cells, Growth factors, Perfusion, Vascular surgery",
author = "Waters, {Richard E.} and Terjung, {Ronald L.} and Peters, {Kevin G.} and Annex, {Brian H.}",
year = "2004",
month = "8",
day = "1",
doi = "10.1152/japplphysiol.00107.2004",
language = "English (US)",
volume = "97",
pages = "773--780",
journal = "Journal of Applied Physiology Respiratory Environmental and Exercise Physiology",
issn = "8750-7587",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - Preclinical models of human peripheral arterial occlusive disease

T2 - Implications for investigation of therapeutic agents

AU - Waters, Richard E.

AU - Terjung, Ronald L.

AU - Peters, Kevin G.

AU - Annex, Brian H.

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Peripheral arterial occlusive disease (PAOD) is now recognized as a combination of clinical syndromes that are associated with significant morbidity and mortality. The primary pathophysiology of PAOD is impaired perfusion to the lower extremity. Effective pharmacotherapy designed to increase perfusion in PAOD is lacking, and revascularization options are suboptimal. New and more efficacious therapies that improve blood flow are definitely needed, and thus designing, describing, and validating these new therapies in preclinical PAOD models will be essential. This study describes the various preclinical PAOD models presently in use, correlates the models to human PAOD, and reviews the available end points that can be used to detect a response to therapy.

AB - Peripheral arterial occlusive disease (PAOD) is now recognized as a combination of clinical syndromes that are associated with significant morbidity and mortality. The primary pathophysiology of PAOD is impaired perfusion to the lower extremity. Effective pharmacotherapy designed to increase perfusion in PAOD is lacking, and revascularization options are suboptimal. New and more efficacious therapies that improve blood flow are definitely needed, and thus designing, describing, and validating these new therapies in preclinical PAOD models will be essential. This study describes the various preclinical PAOD models presently in use, correlates the models to human PAOD, and reviews the available end points that can be used to detect a response to therapy.

KW - Angiogenesis

KW - Endothelial cells

KW - Growth factors

KW - Perfusion

KW - Vascular surgery

UR - http://www.scopus.com/inward/record.url?scp=3242742203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242742203&partnerID=8YFLogxK

U2 - 10.1152/japplphysiol.00107.2004

DO - 10.1152/japplphysiol.00107.2004

M3 - Article

C2 - 15107408

AN - SCOPUS:3242742203

VL - 97

SP - 773

EP - 780

JO - Journal of Applied Physiology Respiratory Environmental and Exercise Physiology

JF - Journal of Applied Physiology Respiratory Environmental and Exercise Physiology

SN - 8750-7587

IS - 2

ER -